Hop Claude Huriez Chu Lille
Lille, 59037, France
Location status: Recruiting
Location contact
CONTACT
NCT Number: NCT04587739
Hepatocellular carcinoma (HCC) is the fifth more common cancer in the world, with high mortality rates, due to the low number of patients who are eligible for therapy with curative intent, like surgical resection. Moreover, surgical resection is associated with a high risk of tumor recurrence, because of the tumor seeding through microscopic intrahepatic vessels that surround the tumor, the so-called "microvascular invasion".
To adequately deal with this phenomenon, the surgeon has to perform either an 'anatomical' liver resection, which remove not only the tumor but also the whole corresponding vascular network, or a 'tumorectomy' with resection margins of at least 2 cm. Unfortunately, these principles cannot always be achieved due to underlying liver cirrhosis that is present in more than 80% of patients.
Stereotactic body radiation therapy (SBRT) has been proven to efficiently necrotize or stabilize HCC nodules when surgery is not possible. Our hypothesis is that pre-treatment with SBRT prior to surgical resection of HCC might improve the results through the destruction of possible seeding in the peritumoral environment.
Given the novelty of this therapeutic strategy, it is necessary to verify its feasibility and safety, prior to test its efficacy in patients with HCC. The KARCHeR-1 study aims at making sure that preoperative SBRT would not result in important delays or serious adverse events such as to cancel the planned surgical resection, in patients who otherwise could have benefited from it. This issue is commonly called 'drop-out'. Thirty patients are expected to be included in the KARCHeR-1 study, which would be in favor of continuing to evaluate this therapeutic strategy if less than 3 drop-outs occur, and would be immediately discontinued if 3 drop-outs occur. Other outcomes will also been studied, like intraoperative issues, postoperative morbi-mortality, pathological features on the surgical specimen and its correlation with preoperative imaging, and finally, tumor recurrence and survival.
Interested in participating?
Request Info18 year–70 year
All sexes
Interventional
Phase 1
Lille, 59037, France
Location status: Recruiting
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Stereotactic hypofractionated robotic radiation therapy (24-45 Gy / 3 fractions) followed after 4-6 weeks by conventional hepatectomy (either anatomical liver resection, or non-anatomical liver resection with intention to achieve a minimal 2 cm margin).
Time frame: Five months after the inclusion of the last participating patient
Drop-out rate: proportion of patients in whom surgical resection cannot be achieved, due to (at least one of the following reasons):
Time frame: Postoperative 90 days
Time frame: Postoperative 90 days
Time frame: Postoperative 90 days
Time frame: Postoperative 90 days
Time frame: between before and after stereotactic radiotherapy
Time frame: Postoperative 90 days
Time frame: Postoperative 90 days
defined using the Comprehensive Complication Index and graded with the Dindo-Clavien score
Time frame: Postoperative 90 days
Time frame: Postoperative day 30.
Time frame: Postoperative 24 months
Contact information is provided by the study sponsor or research team.
University Hospital, Lille
Other
A Pilot Study on the Feasibility and Tolerance of Neoadjuvant Hypofractionated, Stereotactic Body Radiation Therapy Prior to Surgical Resection of Uninodular Hepatocellular Carcinoma.
Acronym: KARCHER-1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04912765
Adenocarcinoma, Carcinoma
Singapore
View Trial DetailsNCT07285044
Adenocarcinoma, Adnexal Diseases
Jacksonville, Florida, United States
View Trial DetailsNCT07479485
Adenocarcinoma, Carcinoma
Beijing, Beijing Municipality, China
View Trial DetailsNCT07059494
Adenocarcinoma, Carcinoma
New York, United States
View Trial Details